The United States reached a deal for up to $2.1 billion with pharmaceutical firms Sanofi and GlaxoSmithKline, for the development and (if it is effective) production of up to 100 million doses of a potential COVID-19 vaccine, based on proteins found on SARS-CoV-2. Sanofi’s effort is now a part of Operation Warp Speed, joining the Pfizer-BioNTech, AstraZeneca-University of Oxford, and Novavax Inc. vaccines, as well as the Regeneron antibody treatment.
U.S. and Canada Public
Another Vaccine Candidate Joins Operation Warp Speed
About the author
Latest articles
Related coverage
-
U.S. and Canada Paid
Russian Diesel Production and Potential Exports Show a Dramatic Increase
-
U.S. and Canada
AIPAC, Mainstay of Zionist Lobby, in Retreat
-
U.S. and Canada Paid
Ninth Circuit Rules 2-1 Against Trump's 2025 National Guard Deployment Into Los Angeles
-
Strategic War Danger
U.S. Strategic Nuclear Exercise
